Боковой амиотрофический склероз

Список литературы

Основные статьи

Brooks BR, Miller RG, Swash M, et al; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299. Аннотация

Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurology. 2009;73:1227-1233.Полный текст  Аннотация

Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. 2009;73:1218-1226. [Errata in: Neurology. 2009;73:2134; Neurology. 2010;74:781.]Полный текст  Аннотация

Статьи, указанные как источники

1. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66:647-653. Аннотация

2. Tartaglia MC, Rowe A, Findlater K, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol. 2007;64:232-236.Полный текст  Аннотация

3. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554. Аннотация

4. Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005;4:771-780. Аннотация

5. Beck M, Giess R, Magnus T, et al. Progressive sudomotor dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2002;73:68-70. Аннотация

6. Shimizu T, Kawata A, Kato S, et al. Autonomic failure in ALS with a novel SOD1 gene mutation. Neurology. 2000;54:1534-1537. Аннотация

7. Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001;191:3-9. Аннотация

8. Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68:1002-1007. Аннотация

9. Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589-602. Аннотация

10. Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427:801. Аннотация

11. Rockenstein E, Crews L, Masliah E. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev. 2007;59:1093-1102. Аннотация

12. Okado-Matsumoto A, Fridovich, I. Amyotrophic lateral sclerosis: a proposed mechanism. Proc Natl Acad Sci U S A. 2002;99:9010-9014.Полный текст  Аннотация

13. Urushitani M, Kurisu J, Tsukita K, et al. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem. 2002;83:1030-1042. Аннотация

14. Rakhit R, Cunningham P, Furtos-Matei A, et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem. 2002;277:47551-47556.Полный текст  Аннотация

15. Lipton SA, Gu Z, Nakamura T. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol. 2007;82:1-27. Аннотация

16. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62. Аннотация

17. Borchelt DR. Amyotrophic lateral sclerosis - are microglia killing motor neurons? N Engl J Med. 2006;355:1611-1613. Аннотация

18. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495-505. Аннотация

19. Lin H, Schlaepfer WW. Role of neurofilament aggregation in motor neuron disease. Ann Neurol. 2006;60:399-406. Аннотация

20. van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098.Полный текст  Аннотация

21. Benatar M, Kurent J, Moore DH. Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2009;(1):CD006153. Аннотация

22. Lee CN. Reviewing evidences on the management of patients with motor neuron disease. Hong Kong Med J. 2012;18:48-55.Полный текст  Аннотация

23. Andersen PM, Sims KB, Xin WW, et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:62-73. Аннотация

24. Rowland LP. Hereditary and acquired motor neuron diseases. In: Rowland LP, ed. Merritt's Neurology. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2000:708-714.

25. Pablo J, Banack SA, Cox PA, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzeimer’s disease. Acata Neurol Scand. 2009;120:216-225. Аннотация

26. Kuzuhara S. Revisit to Kii ALS - the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology. Brain Nerve. 2007;59:1065-1074. Аннотация

27. Weisskopf MG, O'Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology. 2005;64:32-37. Аннотация

28. Veldink JH, Kalmijn S, Groeneveld GJ, et al. Physical activity and the association with sporadic ALS. Neurology. 2005;64:241-245. Аннотация

29. Chio A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain. 2005;128:472-476.Полный текст  Аннотация

30. Kamel F, Umbach DM, Munsat TL, et al. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology. 1999;18:194-202. Аннотация

31. Nelson LM, McGuire V, Longstreth WT Jr, et al. Population-based case control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol. 2000;151:156-163.Полный текст  Аннотация

32. Alonso A, Logroscino G, Hernán MA. Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2010;81:1249-1252. Аннотация

33. Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology. 2009;73:1693-1698.Полный текст  Аннотация

34. McGuire V, Longstreth WT Jr, Nelson LM, et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol. 1997;145:1076-1088.Полный текст  Аннотация

35. Kamel F, Umbach DM, Munsat TL, et al. Lead exposure and amyotrophic lateral sclerosis. Epidemiology. 2002;13:311-319. Аннотация

36. Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary neurology series, volume 49. Philadelphia, PA: FA Davis; 1998:480.

37. Rowland LP, Muscular Dystrophy Association. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Advances in neurology, volume 56. New York, NY: Raven Press; 1991:569.

38. Brooks BR, Sanjak M, Belden D, et al. Natural history in amyotrophic lateral sclerosis - impairment, disability, handicap. In: Brown RH Jr., Meininger V, Swash M, eds. Amyotrophic lateral sclerosis. London: Dunitz; 2000:31-58.

39. Shoesmith CL, Findlater K, Rowe A, et al. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry. 2007;78:629-631. Аннотация

40. Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) - revised report of an EFNS task force. Eur J Neurol. 2012;19:360-375. Аннотация

41. Shipe C, Zivkovic SA. Electrodiagnostic evaluation of motor neuron disorders. Am J Electroneurodiagnostic Technol. 2004;44:30-36. Аннотация

42. de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve. 2000;23:344-352. Аннотация

43. Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve. 2000;23:1488-1502. Аннотация

44. Raaphorst J, de Visser M, Linssen WH, et al. The cognitive profile of amyotrophic lateral sclerosis: a meta-analysis. Amyotroph Lateral Scler. 2010;11:27-37. Аннотация

45. Lomen-Hoerth C. Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord. 2004;17:337-341. Аннотация

46. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077-1079. Аннотация

47. Kornberg, AJ, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve. 1994;17:100-104. Аннотация

48. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73-78. Аннотация

49. Gourie-Devi M, Nalini A. Long-term follow-up of 44 patients with brachial monomelic amyotrophy. Acta Neurol Scand. 2003;107:215-220. Аннотация

50. Blexrud MD, Windebank AJ, Daube JR. Long-term follow-up of 121 patients with benign fasciculations. Ann Neurol. 1993;34:622-625. Аннотация

51. Chasens ER, Umlauf MG. Post-polio syndrome. Am J Nurs. 2000;100:60-63;65;67. Аннотация

52. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994 Jul;124 Suppl:96-107. Аннотация

53. Brooks BR, Miller RG, Swash M, et al; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299. Аннотация

54. Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurology. 2009;73:1227-1233.Полный текст  Аннотация

55. Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology. 2005;65:1264-1267. Аннотация

56. Chio A, Bottacchi E, Buffa C, et al. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948-950. Аннотация

57. Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin. 2001;19:829-847. Аннотация

58. National Institute for Health and Care Excellence. Motor neurone disease: assessment and management. Jul 2019 [internet publication].Полный текст

59. Munroe CA, Sirdofsky MD, Kuru T, et al. End-of-life decision making in 42 patients with amyotrophic lateral sclerosis. Respir Care. 2007;52:996-999.Полный текст  Аннотация

60. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447.Полный текст  Аннотация

61. Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. 2009;73:1218-1226. [Errata in: Neurology. 2009;73:2134; Neurology. 2010;74:781.]Полный текст  Аннотация

62. Jia H, Xu YM. Evidence-based evaluation of therapeutic measures for amyotrophic lateral sclerosis [in Chinese]. Chin J Contemp Neurol Neurosurg. 2012;12:275-281.Полный текст

63. Weber G, Bitterman H. Riluzole-induced neutropenia. Neurology. 2004;62:1648. Аннотация

64. Sanofi-Aventis. Rilutek® (riluzole) tablets: prescribing information. November 2012. http://products.sanofi.usПолный текст

65. Morgan RK, McNally S, Alexander M, et al. Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2005;171:269-274.Полный текст  Аннотация

66. Radunovic A, Annane D, Rafiq MK, et al. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017 Oct 6;10:CD004427.Полный текст  Аннотация

67. Aboussouan LS, Khan SU, Meeker DP, et al. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med. 1997;127:450-453. Аннотация

68. Lo Coco D, Marchese S, Pesco MC, et al. Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology. 2006;67:761-765. Аннотация

69. Rabinstein AA, Wijdicks EF. Warning signs of imminent respiratory failure in neurological patients. Semin Neurol. 2003;23:97-104. Аннотация

70. McKim DA, Road J, Avendano M, et al; Canadian Thoracic Society Home Mechanical Ventilation Committee. Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18:197-215.Полный текст  Аннотация

71. Moss AH, Casey P, Stocking CB, et al. Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family, and physician attitudes. Neurology. 1993;43:438-443. Аннотация

72. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;(10):CD007354.Полный текст  Аннотация

73. Katzberg, HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2011;(1):CD004030.Полный текст  Аннотация

74. Chio A, Finnochiaro E, Meineri P, et al; ALS Percutaneous Endoscopic Gastrostomy Study Group. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology. 1999;53:1123-1125. Аннотация

75. ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol. 2015;14:702-709.Полный текст  Аннотация

76. Stone CA, O'Leary N. Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis. J Pain Symptom Manage. 2009;37:246-258. Аннотация

77. Tysnes OB. Treatment of sialorrhea in amyotrophic lateral sclerosis. Acta Neurol Scand Suppl. 2008;188:77-81. Аннотация

78. McGeachan AJ, Mcdermott CJ. Management of oral secretions in neurological disease. Pract Neurol. 2017;17:96-103.Полный текст  Аннотация

79. Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693-702. Аннотация

80. Lui AJ, Byl NN. A systematic review of the effect of moderate intensity exercise on function and disease progression in amyotrophic lateral sclerosis. J Neurol Physical Therapy. 2009;33:68-87. Аннотация

81. Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;(5):CD005229.Полный текст  Аннотация

82. Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry. 1985;48:838-840. Аннотация

83. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28:140-175. Аннотация

84. Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology. 2005;65:62-67.Полный текст  Аннотация

85. Bensimon G, Lacomblez L, Meininger V; ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585-591.Полный текст  Аннотация

86. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1997;49:657-659. Аннотация

87. Dorst J, Cypionka J, Ludolph AC. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:533-536. Аннотация

88. Costa J, Rocha ML, Ferreira J, et al. Botulinum toxin type-B improves sialorrhea and quality of life in bulbar onset amyotrophic lateral sclerosis. J Neurol. 2008;255:545-550. Аннотация

89. Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279-1281. Аннотация

90. Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505-512. Аннотация

91. Weiss MD, Macklin EA, Simmons Z, et al; Mexiletine ALS Study Group. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86:1474-1481.Полный текст  Аннотация

92. Beghi E, Pupillo E, Bonito V, et al; Italian ALS Study Group. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:397-405. Аннотация

93. DiPALS Writing Committee; DiPALS Study Group Collaborators, McDermott CJ, Bradburn MJ, et al. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14:883-892.Полный текст  Аннотация

94. Gonzalez-Bermejo J, Morélot-Panzini C, Tanguy ML, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurol. 2016;15:1217-1227. Аннотация

95. Abdul Wahid SF, Law ZK, Ismail NA, Lai NM. Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2019 Dec 19;(12): CD011742.Полный текст  Аннотация

96. ClinicalTrials.gov. The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from amyotrophic lateral sclerosis (ALS): NCT02588677. http://clinicaltrials.govПолный текст

97. ClinicalTrials.gov. Ibudilast (MN-166) in subjects with amyotrophic lateral sclerosis (ALS) (IBU-ALS-1201): NCT02238626. http://clinicaltrials.govПолный текст

98. ClinicalTrials.gov. AMX0035 in Patients with Amyotrophic Lateral Sclerosis (CENTAUR): NCT03127514 [internet publication].Полный текст

99. ClinicalTrials.gov. Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis (TUDCA-ALS): NCT00877604. November 2014 [internet publication]. Полный текст

100. ClinicalTrials.gov. Single and multiple dose study of BIIB067 in adults with amyotrophic lateral sclerosis (ALS): NCT02623699. http://clinicaltrials.govПолный текст

101. Turner MR, Parton MJ, Shaw CE, et al. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry. 2003;74:995-997. Аннотация

102. Chiò A, Logroscino G, Hardiman O, et al; Eurals Consortium. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310-323. Аннотация

103. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve. 1989;12:833-841. Аннотация

104. Eisen A, Schulzer M, MacNeil M, et al. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve. 1993;16:27-32. Аннотация

105. Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390-392. Аннотация

Использование этого контента попадает под действие нашего заявления об отказе от ответственности